FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137948257> ?p ?o ?g. }

• W2137948257 endingPage "201" @default.
• W2137948257 startingPage "201" @default.
• W2137948257 abstract "Effectiveness of the association between carbamazepine and peripheral analgesic block with ropivacaine for the treatment of trigeminal neuralgia Laurinda Lemos1,2, Ramalho Fontes3, Sara Flores2, Pedro Oliveira4, Armando Almeida11Life and Health Sciences Research Institute (ICVS), School of Health Sciences, Campus de Gualtar, University of Minho, Braga, Portugal; 2Hospital Center of Alto Ave, Unit of Fafe, Fafe, Portugal; 3Department of Neurology, Hospital São Marcos, Braga, Portugal; 4Products and Systems Engineering, Campus de Azurém, University of Minho, Guimarães, PortugalAbstract: Treatment of trigeminal neuralgia (TN) is achieved by using adjuvant analgesics like antiepileptics, with carbamazepine (CBZ) being the first-line approach for TN patients, although side effects may be present. Other approaches using gabapentin, namely when associated with peripheral analgesic block of TN trigger points with the local anesthetic ropivacaine (ROP), resulted in decreased pain and daily drug intake (reduced side effects). This study evaluates if the association between CBZ and the peripheral block with ROP reinforces the clinical value of CBZ. In this parallel, double-blinded study, idiopathic TN patients were randomized to receive during 4 weeks either CBZ (CBZ; n = 21) or CBZ associated with the peripheral analgesic block using ROP (CBZ + ROP; n = 24). The primary outcome measures were the following: i) pain intensity, evaluated by the numerical rating scale; ii) number of pain crises; and iii) number needed to treat. Evaluation points were at the beginning (day 1) and end (day 29) of treatment and after a follow-up of 5 months (month 6). Both protocols resulted in a decrease of pain intensity and number of pain crises, but only the association CBZ + ROP showed i) a significant stronger reduction in pain intensity at month 6 and ii) a significant decrease in the daily dose of CBZ given to patients (both at day 29 and month 6). In contrast, the daily dose in CBZ-only patients remained constant or even increased. The number needed to treat for the association CBZ + ROP over the CBZ protocol reduced from 5 at the end of the 4-week treatment to 3 after the 5-month follow-up. Data reinforce the use of CBZ as a primary tool to control pain in TN patients, as the association CBZ + ROP i) improves the clinical qualities of CBZ, ii) strongly reduces the daily dose of CBZ, and iii) reduces the potential side effects attributed to high doses of CBZ.Keywords: trigeminal neuralgia, carbamazepine, ropivacaine, therapeutical association, pain intensity, daily dose" @default.
• W2137948257 created "2016-06-24" @default.
• W2137948257 creator A5000719835 @default.
• W2137948257 creator A5033399785 @default.
• W2137948257 creator A5043618203 @default.
• W2137948257 creator A5067564405 @default.
• W2137948257 creator A5091700409 @default.
• W2137948257 date "2010-10-01" @default.
• W2137948257 modified "2023-10-16" @default.
• W2137948257 title "Effectiveness of the association between carbamazepine and peripheral analgesic block with ropivacaine for the treatment of trigeminal neuralgia" @default.
• W2137948257 cites W1503275349 @default.
• W2137948257 cites W190156976 @default.
• W2137948257 cites W1964190147 @default.
• W2137948257 cites W1972991130 @default.
• W2137948257 cites W1977786890 @default.
• W2137948257 cites W1980762531 @default.
• W2137948257 cites W1981435820 @default.
• W2137948257 cites W1982900907 @default.
• W2137948257 cites W1996343181 @default.
• W2137948257 cites W2001956806 @default.
• W2137948257 cites W2005725042 @default.
• W2137948257 cites W2008023699 @default.
• W2137948257 cites W2016178396 @default.
• W2137948257 cites W2033614870 @default.
• W2137948257 cites W2039010167 @default.
• W2137948257 cites W2041369808 @default.
• W2137948257 cites W2045664714 @default.
• W2137948257 cites W2047974543 @default.
• W2137948257 cites W2048656464 @default.
• W2137948257 cites W2049381901 @default.
• W2137948257 cites W2051844633 @default.
• W2137948257 cites W2054507992 @default.
• W2137948257 cites W2058155330 @default.
• W2137948257 cites W2062864603 @default.
• W2137948257 cites W2064295454 @default.
• W2137948257 cites W2066791546 @default.
• W2137948257 cites W2068155779 @default.
• W2137948257 cites W2069987842 @default.
• W2137948257 cites W2084567915 @default.
• W2137948257 cites W2092504977 @default.
• W2137948257 cites W2094310013 @default.
• W2137948257 cites W2107017366 @default.
• W2137948257 cites W2108696783 @default.
• W2137948257 cites W2112146030 @default.
• W2137948257 cites W2124339912 @default.
• W2137948257 cites W2148741199 @default.
• W2137948257 cites W2161344815 @default.
• W2137948257 cites W2162024539 @default.
• W2137948257 cites W2164513741 @default.
• W2137948257 cites W2169136511 @default.
• W2137948257 cites W2478733310 @default.
• W2137948257 cites W2480430789 @default.
• W2137948257 cites W2503138491 @default.
• W2137948257 cites W2904326427 @default.
• W2137948257 cites W3113920725 @default.
• W2137948257 doi "https://doi.org/10.2147/jpr.s13154" @default.
• W2137948257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3004633" @default.
• W2137948257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21197324" @default.
• W2137948257 hasPublicationYear "2010" @default.
• W2137948257 type Work @default.
• W2137948257 sameAs 2137948257 @default.
• W2137948257 citedByCount "11" @default.
• W2137948257 countsByYear W21379482572013 @default.
• W2137948257 countsByYear W21379482572015 @default.
• W2137948257 countsByYear W21379482572017 @default.
• W2137948257 countsByYear W21379482572018 @default.
• W2137948257 countsByYear W21379482572019 @default.
• W2137948257 countsByYear W21379482572020 @default.
• W2137948257 countsByYear W21379482572022 @default.
• W2137948257 countsByYear W21379482572023 @default.
• W2137948257 crossrefType "journal-article" @default.
• W2137948257 hasAuthorship W2137948257A5000719835 @default.
• W2137948257 hasAuthorship W2137948257A5033399785 @default.
• W2137948257 hasAuthorship W2137948257A5043618203 @default.
• W2137948257 hasAuthorship W2137948257A5067564405 @default.
• W2137948257 hasAuthorship W2137948257A5091700409 @default.
• W2137948257 hasBestOaLocation W21379482571 @default.
• W2137948257 hasConcept C118552586 @default.
• W2137948257 hasConcept C126322002 @default.
• W2137948257 hasConcept C2778186239 @default.
• W2137948257 hasConcept C2779253243 @default.
• W2137948257 hasConcept C2780269707 @default.
• W2137948257 hasConcept C2780355897 @default.
• W2137948257 hasConcept C2780820201 @default.
• W2137948257 hasConcept C42219234 @default.
• W2137948257 hasConcept C46762472 @default.
• W2137948257 hasConcept C71924100 @default.
• W2137948257 hasConceptScore W2137948257C118552586 @default.
• W2137948257 hasConceptScore W2137948257C126322002 @default.
• W2137948257 hasConceptScore W2137948257C2778186239 @default.
• W2137948257 hasConceptScore W2137948257C2779253243 @default.
• W2137948257 hasConceptScore W2137948257C2780269707 @default.
• W2137948257 hasConceptScore W2137948257C2780355897 @default.
• W2137948257 hasConceptScore W2137948257C2780820201 @default.
• W2137948257 hasConceptScore W2137948257C42219234 @default.
• W2137948257 hasConceptScore W2137948257C46762472 @default.
• W2137948257 hasConceptScore W2137948257C71924100 @default.
• W2137948257 hasLocation W21379482571 @default.

• next